A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study

• Status: Completed
• Trial end date: 2017-04-28
• Target enrollment: 0
• Participant gender: All

Summary

The purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension who are non-/low-responders to latanoprost ophthalmic solution.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Santen Pharmaceutical Co., Ltd.
• Treatments: Latanoprost; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Primary open angle glaucoma or ocular hypertension

Exclusion Criteria:

• Patients at risk of progression of visual field loss

• Patients with severe visual field defect

• Patients with any diseases that preclude participation in this study for safety reasons